LINC01572 is a Novel Prognostic Biomarker and Therapeutic Target in Lung Adenocarcinoma

Yaolin Zheng; Zhenshan Zhang; Xueyan Li; Leilei Wu; Xinliang Liu; Liang Liu; Jiayan Chen; Dongping Wei

doi:10.31083/j.fbl2810257

LINC01572 is a Novel Prognostic Biomarker and Therapeutic Target in Lung Adenocarcinoma

Front Biosci (Landmark Ed). 2023 Oct 20;28(10):257. doi: 10.31083/j.fbl2810257.

Authors

Yaolin Zheng¹, Zhenshan Zhang^{2

3}, Xueyan Li¹, Leilei Wu⁴, Xinliang Liu⁵, Liang Liu⁴, Jiayan Chen², Dongping Wei¹

Affiliations

¹ Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 210006 Nanjing, Jiangsu, China.
² Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 200000 Shanghai, China.
³ Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, 200120 Shanghai, China.
⁴ Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 200433 Shanghai, China.
⁵ Department of Endocrinology, People's Hospital of Xuyi, 211700 Xuyi, Jiangsu, China.

PMID: 37919058
DOI: 10.31083/j.fbl2810257

Abstract

Background: Lung adenocarcinoma (LUAD) is one of the most common and lethal cancer types worldwide. LINC0572 is a long non-coding RNA (lncRNA) that has been associated with the clinical characteristics of several types of malignancy. However, the biological mechanism of LINC0572 in LUAD is still unclear and remains to be elucidated.

Methods: R packages and online bioinformatic tools were used to investigate the biological characteristics of LINC01572, including its abnormal expression, oncogenic role, and clinical prognostic value. In vitro and in vivo experiments were conducted to investigate the biological functions of LINC01572 in tumorigenesis and development. These included colony formation assays, cell migration assays, flow cytometry, cell counting kit-8 (CCK-8) cell proliferation and tumor transplant growth experiments.

Results: Bioinformatics results showed that LINC01572 was overexpressed in both LUAD and lung squamous cell carcinoma (LUSC) patients. LINC01572 overexpression was associated with shorter overall survival (OS) in LUAD. Further study of clinical specimens confirmed that LINC01572 was highly expressed in the tumor tissue of non-small cell lung cancer (NSCLC) patients. In vitro experiments also confirmed that LINC01572 was overexpressed in tumor cell lines. Inhibition of LINC01572 expression significantly impaired cell proliferation, cell migration, and clone formation. Experiments in nude mouse revealed that transplanted tumors with low expression of LINC01572 had significantly slower rates of growth in terms of volume and weight compared to the control group (p < 0.05). In addition, gene set enrichment analysis (GSEA) and immune landscape profiling showed that LINC01572 can promote tumor initiation and progression by deregulating the cell cycle and immunocyte infiltration.

Conclusions: LINC01572 is overexpressed in tumor tissue relative to adjacent normal tissue. Moreover, LUAD patients with high expression of LINC01572 showed a worse survival prognosis. LINC01572 is associated with tumor initiation, progression and immune dysregulation. It therefore has potential value as a novel biomarker and therapeutic target in LUAD.

Keywords: NSCLC; TCGA; experiments; lncRNA; lung adenocarcinoma.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma* / genetics
Adenocarcinoma* / metabolism
Animals
Carcinoma, Non-Small-Cell Lung* / genetics
Humans
Lung / metabolism
Lung Neoplasms* / pathology
Mice
Prognosis
RNA, Untranslated / genetics

Substances

RNA, Untranslated